Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest Expenses (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Interest Expenses for 5 consecutive years, with $15.8 million as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses fell 12.58% year-over-year to $15.8 million; the TTM value through Mar 2026 reached $65.8 million, down 9.7%, while the annual FY2025 figure was $68.1 million, 5.41% down from the prior year.
  • Interest Expenses hit $15.8 million in Q1 2026 for Phathom Pharmaceuticals, down from $16.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $18.6 million in Q4 2024 and bottomed at $2.8 million in Q1 2022.
  • Average Interest Expenses over 5 years is $13.2 million, with a median of $15.8 million recorded in 2026.
  • Year-over-year, Interest Expenses soared 234.07% in 2023 and then decreased 12.85% in 2025.
  • Phathom Pharmaceuticals' Interest Expenses stood at $9.6 million in 2022, then skyrocketed by 35.69% to $13.0 million in 2023, then surged by 42.7% to $18.6 million in 2024, then decreased by 11.69% to $16.4 million in 2025, then fell by 3.79% to $15.8 million in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $15.8 million, $16.4 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.